Engineering a niche supporting hematopoietic stem cell development using integrated single-cell transcriptomicsBrandon Hadland(Seattle Children's Hospital), Irwin D. Bernstein(Fred Hutch Cancer Center)Nature CommunicationsMarch 24, 202210.1038/s41467-022-28781-zCited by 54SaveCiteExport RISWatch citationsRelated PapersSelective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate|Blood|1999|456Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate|Blood|1999|439SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML|Blood|2013|385A requirement for Notch1 distinguishes 2 phases of definitive hematopoiesis during development|Blood|2004|236Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.|PubMed|1996|212